Denali Therapeutics

DNLI55

$30.91arrow_drop_up0.47%$0.14

DNLI55

$30.91

arrow_drop_up0.47%$0.14

Performance History

Key Stats
Open	$30.80
Prev. Close	$30.77
EPS	-2.86
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	30.15	30.95
52 Week Range	14.56	31.00

Ratios







EPS	-2.86

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Denali Therapeutics (DNLI)

Denali Therapeutics Inc (DNLI) is a biotechnology company that focuses on developing therapies for neurodegenerative diseases. The company was founded in 2015 and is headquartered in South San Francisco, California. Denali Therapeutics is known for its innovative approach to drug development, utilizing a combination of small molecules, antibodies, and gene therapies to target the underlying causes of neurodegenerative diseases such as Alzheimer's and Parkinson's.

Denali Therapeutics has a strong pipeline of potential therapies, with several candidates in various stages of development. One of the company's lead programs is focused on developing a treatment for Alzheimer's disease, a devastating condition that affects millions of people worldwide. Denali Therapeutics is also working on treatments for Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Ryan J. Watts Ph.D.
Headquarters: South San Francisco
Employees: 438
Exchange: NASDAQ

Keep an eye on Denali Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Denali Therapeutics 's (DNLI) price per share?

The current price per share for Denali Therapeutics (DNLI) is $30.92. The stock has seen a price change of $0.14 recently, indicating a 0.47% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Denali Therapeutics (DNLI)?

For Denali Therapeutics (DNLI), the 52-week high is $31, which is 0.27% from the current price. The 52-week low is $14.56, the current price is 112.33% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Denali Therapeutics (DNLI) a growth stock?

Denali Therapeutics (DNLI) has shown an average price growth of 0.41% over the past three years. It has received a score of 16 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Denali Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Denali Therapeutics (DNLI) stock price performance year to date (YTD)?

As of the latest data, Denali Therapeutics (DNLI) has a year-to-date price change of 44.53%. Over the past month, the stock has experienced a price change of 30.61%. Over the last three months, the change has been 50.95%. Over the past six months, the figure is 53.58%. Looking at a longer horizon, the five-year price change stands at 56.69%.

help

Is Denali Therapeutics (DNLI) a profitable company?

Denali Therapeutics (DNLI) has a net income of -$145.22M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 94.94% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -39.09K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $330.53M, although specific revenue growth data is currently not available. The gross profit is $313.8M. Operating income is noted at -$196.7M. Furthermore, the EBITDA is -$494.61M.

help

What is the market capitalization of Denali Therapeutics (DNLI)?

Denali Therapeutics (DNLI) has a market capitalization of $4.41B. The average daily trading volume is 1.08M, indicating the stock's liquidity and investor engagement.